Table 4.
Logistic regression analysis for the associations among VAI, LAP indexes, parameters used for indexes calculations, and DM2 development
| Predictors | Unadjusted OR (95%CI) | P | Nagelkerke R 2 |
|---|---|---|---|
| BMI, kg/m2 | 1.140 (1.079‐1.205) | <.001 | .115 |
| WC, cm | 1.068 (1.046‐1.091) | <.001 | .198 |
| HDL‐c, mmol/L | 0.095 (0.046‐0.198) | <.001 | .209 |
| TG, mmol/L | 1.718 (1.295‐2.279) | <.001 | .083 |
| LAP | 1.016 (1.010‐1.021) | <.001 | .162 |
| VAI | 1.292 (1.133‐1.474) | <.001 | .092 |
| Age, years | 1.052 (1.033‐1.071) | <.001 | .142 |
| Hypolipemics | 3.120 (1.814‐5.367) | <.001 | .081 |
| Adjusted OR (95%CI) | P | Nagelkerke R 2 | |
|---|---|---|---|
| Model 1 | |||
| BMI, kg/m2 | 0.963 (0.863‐1.076) | .513 | .411 |
| WC, cm | 1.050 (1.006‐1.097) | .027 | |
| HDL‐c, mmol/L | 0.142 (0.053‐0.385) | <.001 | |
| TG, mmol/L | 0.954 (0.728‐1.249) | .730 | |
| Age, years | 1.050 (1.021‐1.086) | .001 | |
| Hypolipemics | 2.130 (1.150‐4.108) | .024 | |
| Model 2 | |||
| VAI | 1.136 (0.998‐1.295) | .053 | .318 |
| Age, years | 1.064 (1.034‐1.095) | <.001 | |
| Hypolipemics | 2.040 (1.020‐3.770) | .023 | |
| Model 3 | |||
| TG, mmol/L | 1.200 (0.934‐1.536) | .155 | .356 |
| WC, cm | 1.052 (1.022‐1.082) | <.001 | |
| Age, years | 1.054 (1.023‐1.086) | <.001 | |
| Hypolipemics | 2.041 (1.086‐3.840) | .027 | |
| Model 4 | |||
| LAP | 1.010 (1.003‐1.017) | .005 | .333 |
| Age, years | 1.061 (1.031‐1.092) | <.001 | |
| Hypolipemics | 1.985 (1.065‐3.698) | .031 | |
Model 1: age, BMI, WC, HDL‐c, TG, hsCRP, ALT, GGT, uric acid, bilirubin, creatinine, eGFRMDRD (continuous variables); gender, smoking status, hypolipemics, and antihypertensive therapies (categorical variables).
Model 2: age, VAI, hsCRP, ALT, GGT, uric acid, bilirubin, creatinine, eGFRMDRD (continuous variables); gender, smoking status, hypolipemics, and antihypertensive therapies (categorical variables).
Model 3: age, WC, TG, hsCRP, ALT, GGT, uric acid, bilirubin, creatinine, eGFRMDRD (continuous variables); gender, smoking status, hypolipemics, and antihypertensive therapies (categorical variables).
Model 4: age, LAP, hsCRP, ALT, GGT, uric acid, bilirubin, creatinine, eGFRMDRD (continuous variables); gender, smoking status, hypolipemics, and antihypertensive therapies (categorical variables).